Olaparib upregulates the expression of death receptor TRAIL-R2 and significantly increases tumor cell sensitivity to NK killing and antibody-dependent cellular cytotoxicity (ADCC) in both BRCA WT and mutant prostate carcinoma cells[13]. The gene discussed is TNFRSF10B; the disease is prostate carcinoma.